(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 March 2013 (21.03.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/040309 A2

(51) International Patent Classification:
C07K 14/47 (2006.01) *C12N 15/12* (2006.01)
C07K 19/00 (2006.01) *C12N 15/63* (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:
PCT/US2012/055336

(22) International Filing Date:
14 September 2012 (14.09.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/535,913 16 September 2011 (16.09.2011) US

(71) Applicant *(for all designated States except US)*: **FATE THERAPEUTICS, INC.** [US/US]; 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US).

(72) Inventor; and
(71) Applicant : **BENNETT, Monica** [US/US]; 4184 Misty Ridge, San Diego, California 92130 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LEE, Tom Tong** [CN/US]; 9308 Galvin Avenue, San Diego, California 92126 (US). **FITCH, Michael J.** [US/US]; 3147 Avenida Olmeda, Carlsbad, California 92009 (US). **LAI, Kevin** [US/US]; 8233 Station Village Lane, Unit 2305, San Diego, California 92108 (US). **FLYNN, Peter** [US/US]; 2834 Arnoldson Avenue, San Diego, California 92122 (US).

(74) Agents: **MCDONALD, Michael J.** et al.; Cooley LLP, 777 - 6th Street, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM,

[Continued on next page]

(54) Title: WNT COMPOSITIONS AND THERAPEUTIC USES OF SUCH COMPOSITIONS

(57) Abstract: The invention provides novel Wnt polypeptides that have improved production characteristics, solubility, systemic delivery, and tissue uptake, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth.




FIG. 8A

WO 2013/040309 A2

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*